Edition:
United Kingdom

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

4.31USD
15 Oct 2018
Change (% chg)

$0.07 (+1.65%)
Prev Close
$4.24
Open
$4.18
Day's High
$4.36
Day's Low
$3.92
Volume
29,158
Avg. Vol
23,723
52-wk High
$6.30
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA.APTEVO THERAPEUTICS INC- ‍EXPECTS TO FILE 2 IND APPLICATIONS IN 2018 FOR 2 BISPECIFIC ANTIBODY CANDIDATES, APVO436 AND APVO210​.  Full Article

Aptevo Therapeutics files mixed shelf of up to $150 mln
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

Aptevo Therapeutics reports third quarter 2017 financial results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics reports third quarter 2017 financial results.Q3 earnings per share $1.77.  Full Article

BRIEF-Aptevo Therapeutics Q1 Loss Per Share $0.63

* APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS